Animal Study shows Baricitinib reduces disease severity in infants with MKD — Evidence Review

Scientists at the Garvan Institute of Medical Research have identified a previously overlooked defect in natural killer (NK) cells as the driver of inflammation in mevalonate kinase deficiency (MKD), overturning decades-old beliefs centered on macrophages. Findings from related studies generally support the move toward more precise, mechanism-based treatments for rare immune disorders, though direct evidence for this NK cell pathway in MKD is newly described.

• Previous research into rare immune diseases has focused on T and B cell dysfunction and highlighted advances in both diagnosis and treatment, but NK cell dysfunction in MKD represents a novel mechanism not previously emphasized in the literature 1 3 4.
• The new study's exploration of JAK inhibitors for MKD aligns with trends in immune therapy, where targeted small molecule inhibitors and biologics are increasingly being adapted for rare autoinflammatory disorders 4.
• While some prior case reports suggested alternative treatments like colchicine for mild MKD, the current study provides the first clinical evidence that blocking interferon gamma signaling with a JAK inhibitor can reduce disease severity in severe MKD, potentially expanding therapeutic options 6.

Study Overview and Key Findings

Understanding why routine infections can trigger life-threatening inflammation in some individuals with rare immune disorders remains a critical challenge. This study addresses a longstanding gap by identifying natural killer (NK) cell dysfunction as a primary cause of autoinflammation in mevalonate kinase deficiency (MKD), marking a significant departure from previous models that focused on macrophage-driven inflammation. The findings not only clarify the underlying pathophysiology of MKD but also highlight new therapeutic possibilities, especially for patients who do not respond to standard treatments.

Property	Value
Study Year	2026
Organization	Garvan Institute of Medical Research, Monash University, Royal Children’s Hospital
Journal Name	Immunity
Authors	Marcia A. Munoz, Iona S. Schuster, James Cremasco, Etienne N. Masle-Farquhar, Oliver P. Skinner, Zoe J. Vandeleur, Maté Biro, Daryan Kempe, William D. Renton, Sam Mehr, Charlotte Abell-King, Szun Szun Tay, Ryan C. Chai, Samar Ojaimi, John J. Zaunders, Geetha Rao, Ariel Castro-Martinez, Lisette van de Corput, Andrew N. McCorkindale, Leonard D. Goldstein, Xiaohong Li, Flore Wouters, Daniel L. Kastner, Ignatius Chua, Nicole L. Fewings, Fiona C. McKay, Catharina M. Mulders-Manders, Robert A. Brink, Stuart G. Tangye, Ivona Aksentijevich, Cindy S. Ma, Jeroen van der Hilst, Joost Frenkel, Mariapia A. Degli-Esposti, Michael J. Rogers
Population	Patients with mevalonate kinase deficiency (MKD)
Methods	Animal Study
Outcome	NK cell dysfunction, interferon gamma production
Results	Baricitinib reduced disease severity in an infant with MKD.

Literature Review: Related Studies

To understand how the new study fits into the broader context of research on rare immune disease mechanisms and treatments, we searched the Consensus database, which includes over 200 million research papers. The following queries were used:

1. baricitinib immune disease MKD
2. rare immune disease treatment outcomes
3. infant MKD disease severity reduction

Summary Table of Related Study Findings

Topic	Key Findings
How do immune cell defects drive autoinflammation in rare diseases?	- Most research highlights T and B cell dysfunction as primary drivers in severe combined immunodeficiencies, but NK cell defects are less frequently examined in this context 1 3. - Some recent studies have noted that immune dysregulation can involve a range of immune cell types, including NK cells, and that phenotype-genotype relationships are complex 4.
What are the current and emerging treatments for rare autoinflammatory or immunodeficiency disorders?	- Hematopoietic stem cell transplantation, gene therapy, and small molecule inhibitors (including JAK inhibitors) are increasingly used in rare immune disorders 2 3 4. - Some case reports suggest colchicine may be effective for mild MKD, but standard therapies often fail in severe cases 6.
What factors influence treatment outcomes and prognosis in infants with immune deficiencies?	- Early diagnosis and intervention—especially before onset of infections—are critical to improve survival and long-term outcomes in infants with severe immune deficiencies 1 2. - NK cell and T cell reconstitution after gene therapy or transplantation is associated with better clinical outcomes and may predict recovery 2 3.
How are diagnostic and therapeutic options evolving for rare immune disorders?	- Advances in genetic testing, newborn screening, and international collaboration have accelerated diagnosis and broadened treatment options for rare immune diseases 4. - The use of small molecule inhibitors and biologics is expanding beyond common autoimmune diseases to rare autoinflammatory disorders 4 5.

---

How do immune cell defects drive autoinflammation in rare diseases?

While most earlier studies on rare immune deficiencies focused on T and B cell defects, the new research highlights NK cell dysfunction as a central driver in MKD, shifting the paradigm of disease mechanism. This broadens the understanding of immune dysregulation in inherited disorders, where multiple immune cell types—and not just adaptive immune cells—can cause pathogenic inflammation 1 3 4.

• The literature on severe combined immunodeficiencies (SCID) primarily emphasizes T cell and, to a lesser extent, NK cell dysfunction, but the direct link between NK cell defects and autoinflammation in MKD had not been established 1.
• Recent reviews acknowledge increasing recognition of diverse immune cell involvement and genotype–phenotype variability in inborn errors of immunity 4.
• The new study uniquely implicates a failure in NK cell granule release and compensation via excess interferon gamma production, a mechanism not previously described in the context of MKD 1 4.
• This challenges long-held beliefs and may prompt reexamination of the role of innate immune cells in other rare autoinflammatory disorders 4.

What are the current and emerging treatments for rare autoinflammatory or immunodeficiency disorders?

Treatment strategies for rare immune diseases are evolving, with increasing use of targeted therapies such as JAK inhibitors, gene therapy, and biologics. The new study supports this trend by demonstrating potential benefit from baricitinib in MKD, especially where conventional therapies fail 2 3 4 6.

• Hematopoietic cell transplantation remains standard for many severe immunodeficiencies, but alternatives like gene therapy and small molecule inhibitors are now viable where suitable donors are lacking 2 3 4.
• JAK inhibitors, already established in other autoimmune and inflammatory conditions, are being repurposed for rare autoinflammatory diseases, as exemplified by baricitinib use in severe MKD 4.
• Case reports of colchicine use in mild MKD suggest that treatment responses may be genotype- and severity-dependent 6.
• Expanding the repertoire of therapeutics is driven by an improved understanding of disease mechanisms, such as the new NK cell findings in MKD 4.

What factors influence treatment outcomes and prognosis in infants with immune deficiencies?

Early diagnosis—especially before the onset of infections—remains crucial for improving outcomes in infants with severe immunodeficiencies. The new study’s clinical intervention in an infant with severe MKD aligns with evidence that prompt, mechanism-based therapy can reduce disease severity and improve prognosis 1 2 3.

• Outcomes in SCID and related disorders are best when definitive therapy is administered early, emphasizing the importance of newborn screening and rapid diagnosis 1 2.
• Active infection at the time of intervention is associated with poorer survival and event-free rates, underscoring the need for early, preemptive treatment 2.
• Successful immune reconstitution—including NK cell recovery—predicts better long-term outcomes after gene therapy or transplantation 2 3.
• The application of personalized medicine, informed by genetic and immune profiling, is increasingly feasible for rare immune disorders 1 4.

How are diagnostic and therapeutic options evolving for rare immune disorders?

Advances in genetic testing, newborn screening, and international research networks have accelerated the pace of discovery and improved access to novel therapies in rare immune diseases. The new findings in MKD exemplify this progress, revealing new diagnostic and therapeutic pathways 4 5.

• Next-generation sequencing and molecular diagnostics have identified new disease genes and clarified complex immunophenotypes, enabling more precise classification and treatment 4.
• Awareness of rare immune-related adverse events from therapies like immune checkpoint inhibitors has led to more individualized and mechanism-based management strategies 5.
• The expansion of small molecule inhibitors and biologics for rare autoinflammatory conditions is supported by both new mechanistic insights and clinical evidence 4.
• Improved collaboration among researchers and clinicians is shortening the diagnostic odyssey and facilitating timely, targeted interventions for rare disease patients 4 5.

Future Research Questions

Although the new study provides pivotal insights into the mechanism and treatment of MKD, further research is needed to explore the generalizability of these findings, optimize therapeutic strategies, and deepen understanding of immune dysregulation in rare autoinflammatory disorders.

Research Question	Relevance
How common is NK cell dysfunction across different forms of MKD and related prenylopathies?	Determining the prevalence and spectrum of NK cell dysfunction in various MKD genotypes and related disorders will clarify whether this mechanism is universal or restricted to specific patient subsets 1 4.
What are the long-term safety and efficacy outcomes of JAK inhibitor therapy in infants and children with MKD?	Long-term data are needed to assess sustained disease control, safety, and potential immune effects of JAK inhibitors in the pediatric MKD population, as most current evidence comes from single cases or adult studies 2 4.
How does NK cell dysfunction contribute to the pathogenesis of other autoinflammatory or immunodeficiency syndromes?	Exploring NK cell roles in other rare immune disorders may reveal shared mechanisms and therapeutic targets, expanding the impact of the current study's findings 1 3 4.
Can early genetic and immune screening improve diagnosis and treatment outcomes in patients with MKD and related disorders?	Early diagnosis has been shown to improve outcomes in SCID and other severe immune deficiencies; assessing its impact in MKD could reduce morbidity and facilitate timely intervention 1 2 4.
What are the molecular mechanisms by which defective NK cells induce excessive interferon gamma production in MKD?	Understanding the detailed pathways linking NK cell granule release defects to interferon gamma overproduction may reveal new drug targets and inform future therapies beyond JAK inhibition 4.